(EMAILWIRE.COM, January 19, 2019 ) Regenerative Medicine Market Research report gives a detailed overview of major drivers, restraints, challenges, opportunities, market trends, and strategies impacting the market along with the estimates and forecasts of the revenue and market share analysis.

Orthopedic & Musculoskeletal Disorders application will drive the growth of regenerative medicine market:

Based on therapy, the Regenerative medicine market is segmented into cell therapy, gene therapy, tissue engineering, and immunotherapy. Immunotherapy is the fastest growing segment in the global Regenerative Medicine market, during the forecast period. This market is also segmented by application. By application, the segments are orthopedic & musculoskeletal disorders, dermatology, cardiology, diabetes, central nervous system diseases, and other applications. Oncology is the fastest growing application market in the global Regenerative Medicine market

According to WR Hambrecht & Co., a leading investment banking firm, the number of surgical procedures using orthobiologics and bone graft substitutes will continue to increase in the near future. Moreover, according to the U.S. Centers for Medicare and Medicaid Services, approximately 900,000 surgeries (which require bone regeneration) are performed annually in the U.S. Of these, spinal fusion (about 450,000 surgeries performed annually in the U.S.) was the most common surgery.

Speak To Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=65442579

Factors impacting Growth of Regenerative Medicine Market:
The cell-based products are expected to dominate the global Regenerative Medicine market. Increasing funding from several agencies and private organizations for the research and development of cell therapies, growing inclination of the healthcare industry towards stem cell research, and increasing global awareness about the benefits of stem cell therapies are driving the growth of the cell therapy segment.

The key players in Regenerative Medicine Market:
organogenesis Inc. (U.S.), Osiris Therapeutics, Inc. (U.S.), Vericel Corporation (U.S.), Stryker Corporation (U.S.), and NuVasive, Inc. (U.S.). The key players in the acellular products segment are Medtronic (Ireland), Acelity (KCI Concepts) (U.S.), Integra LifeSciences (U.S.), Cook Biotech Inc. (U.S.), and C.R. Bard (U.S.).